A perfect mismatch: haploidentical hematopoietic stem cell transplantation overtakes a bend.
作者信息
Lv Meng, Guo Hui-Dong, Huang Xiao-Jun
机构信息
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Peking-Tsinghua Center for Life Sciences, Beijing, China.
出版信息
Cell Mol Immunol. 2023 Aug;20(8):978-980. doi: 10.1038/s41423-023-01007-y. Epub 2023 Mar 30.
Abstract
摘要
相似文献
1
A perfect mismatch: haploidentical hematopoietic stem cell transplantation overtakes a bend.一个完美的不匹配：单倍体相合造血干细胞移植迎来转折。
Cell Mol Immunol. 2023 Aug;20(8):978-980. doi: 10.1038/s41423-023-01007-y. Epub 2023 Mar 30.
2
A single-center experience of haploidentical stem cell transplantation in hematological malignancies.单中心亲缘单倍体造血干细胞移植治疗血液系统恶性肿瘤的经验
Turk J Med Sci. 2023 Feb;53(1):352-359. doi: 10.55730/1300-0144.5591. Epub 2023 Feb 22.
3
The rationale behind grafting haploidentical hematopoietic stem cells.同种异体造血干细胞移植的基本原理。
Hematology. 2024 Dec;29(1):2347673. doi: 10.1080/16078454.2024.2347673. Epub 2024 May 7.
4
Stable multilineage chimerism without graft versus host disease following nonmyeloablative haploidentical hematopoietic cell transplantation.非清髓性单倍体相合造血细胞移植后无移植物抗宿主病的稳定多谱系嵌合状态
Transplantation. 2006 Jun 27;81(12):1677-85. doi: 10.1097/01.tp.0000226061.59196.84.
5
Research advances on haploidentical hematopoietic stem cell transplantation in the treatment of severe aplastic anemia in children.儿童重型再生障碍性贫血单倍体造血干细胞移植治疗的研究进展。
Zhongguo Dang Dai Er Ke Za Zhi. 2021 Aug 15;23(8):854-859. doi: 10.7499/j.issn.1008-8830.2105073.
6
[Effect of Graft Composition on Acute Graft-Versus-Host Disease in Aplastic Anemia after Haploidentical Hematopoietic Stem Cell Transplantation].[单倍体相合造血干细胞移植后再生障碍性贫血中移植物组成对急性移植物抗宿主病的影响]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2018 Oct;26(5):1442-1446. doi: 10.7534/j.issn.1009-2137.2018.05.031.
7
Comparison of 2 Different Doses of Antithymocyte Globulin in Conditioning Regimens for Haploidentical Hematopoietic Stem Cell Transplantation.单倍体造血干细胞移植预处理方案中两种不同剂量抗胸腺细胞球蛋白的比较
Exp Clin Transplant. 2022 Jan;20(1):69-76. doi: 10.6002/ect.2021.0003. Epub 2021 Aug 9.
8
Impact of ABO incompatibility on patients' outcome after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia - a report from the Acute Leukemia Working Party of the EBMT.ABO血型不相容对急性髓系白血病单倍体相合造血干细胞移植患者预后的影响——欧洲血液与骨髓移植协会急性白血病工作组的报告
Haematologica. 2017 Jun;102(6):1066-1074. doi: 10.3324/haematol.2016.160804. Epub 2017 Mar 2.
9
[Repeated haploidentical allogeneic hematopoietic stem cell transplantation with TCR αβ/CD19 depletion in patient with primary myelofibrosis. Case report].[原发性骨髓纤维化患者重复单倍体相合异基因造血干细胞移植并TCRαβ/CD19去除。病例报告]
Ter Arkh. 2021 Jul 23;93(7):805-810. doi: 10.26442/00403660.2021.07.200948.
10
Comparison of matched sibling, unrelated and haploidentical donors in hematopoietic stem cell transplantation. A real-world experience from the Argentine Group for Bone Marrow Transplantation and Cell Therapy (GATMO-TC).造血干细胞移植中匹配同胞、无关和单倍体相合供者的比较。来自阿根廷骨髓移植与细胞治疗小组（GATMO-TC）的真实世界经验。
Medicina (B Aires). 2020;80(6):654-662.
引用本文的文献
1
Lack of Evidence Supporting a Significant Benefit of Pre-Transplant Consolidation Therapy in AML CR2 Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.缺乏证据支持移植前巩固治疗对接受异基因造血干细胞移植的急性髓系白血病完全缓解2期患者有显著益处。
Cancers (Basel). 2025 Apr 19;17(8):1364. doi: 10.3390/cancers17081364.
2
Systematic mining and quantification reveal the dominant contribution of non-HLA variations to acute graft-versus-host disease.系统挖掘和定量分析揭示了非HLA变异对急性移植物抗宿主病的主要贡献。
Cell Mol Immunol. 2025 May;22(5):501-511. doi: 10.1038/s41423-025-01273-y. Epub 2025 Mar 4.
3
Distinct Immune Homeostasis Remodeling Patterns after HLA-Matched and Haploidentical Transplantation.HLA 匹配和单倍体移植后不同的免疫稳态重塑模式。
Adv Sci (Weinh). 2024 Oct;11(39):e2400544. doi: 10.1002/advs.202400544. Epub 2024 Sep 3.
4
Graft CD8 T-cell-based risk system predicts survival in antithymocyte globulin-based myeloablative haploidentical peripheral blood stem cell transplantation.基于移植物CD8 T细胞的风险系统可预测抗胸腺细胞球蛋白预处理的清髓性单倍体相合外周血干细胞移植的生存率。
Clin Transl Immunology. 2024 Jan 12;13(1):e1484. doi: 10.1002/cti2.1484. eCollection 2024.
本文引用的文献
1
Development of allogeneic hematopoietic stem cell transplantation in 2022: Regenerating "Groot" to heal the world.2022年异基因造血干细胞移植的发展：重塑“格鲁特”治愈世界。
Innovation (Camb). 2023 Jan 2;4(1):100373. doi: 10.1016/j.xinn.2023.100373. eCollection 2023 Jan 30.
2
A vision for the future of allogeneic hematopoietic stem cell transplantation in the next decade.对未来十年异基因造血干细胞移植的展望。
Sci Bull (Beijing). 2022 Oct 15;67(19):1921-1924. doi: 10.1016/j.scib.2022.09.004. Epub 2022 Sep 5.
3
Haematopoietic stem-cell transplantation in China in the era of targeted therapies: current advances, challenges, and future directions.中国靶向治疗时代的造血干细胞移植：当前的进展、挑战和未来方向。
Lancet Haematol. 2022 Dec;9(12):e919-e929. doi: 10.1016/S2352-3026(22)00293-9.
4
The lower relapse rate and better survival advantages of haploidentical allograft compared with HLA-matched sibling donor allografts for intermediate- and adverse-risk AML patients with pretransplantation minimal residual disease.对于移植前微小残留病的中危和高危急性髓系白血病患者，单倍体同基因移植相较于人类白细胞抗原匹配的同胞供体移植具有更低的复发率和更好的生存优势。
Bone Marrow Transplant. 2023 Feb;58(2):215-218. doi: 10.1038/s41409-022-01872-7. Epub 2022 Nov 14.
5
Comparable long-term outcomes between upfront haploidentical and identical sibling donor transplant in aplastic anemia: a national registry-based study.在再生障碍性贫血患者中，直接使用单倍体相合供者和同胞全相合供者进行移植的长期疗效相当：一项基于国家注册登记研究的结果。
Haematologica. 2022 Dec 1;107(12):2918-2927. doi: 10.3324/haematol.2022.280758.
6
Assessment of Patient-Specific Human Leukocyte Antigen Genomic Loss at Relapse After Antithymocyte Globulin-Based T-Cell-Replete Haploidentical Hematopoietic Stem Cell Transplant.抗胸腺细胞球蛋白预处理的单倍体相合造血干细胞移植后复发时的患者特异性人类白细胞抗原基因组缺失评估
JAMA Netw Open. 2022 Apr 1;5(4):e226114. doi: 10.1001/jamanetworkopen.2022.6114.
7
Donor-derived multiple leukemia antigen-specific T-cell therapy to prevent relapse after transplant in patients with ALL.供者来源的多种白血病抗原特异性 T 细胞治疗预防 ALL 患者移植后复发。
Blood. 2022 Apr 28;139(17):2706-2711. doi: 10.1182/blood.2021014648.
8
The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update.中华血液学分会关于异基因造血干细胞移植适应证、预处理方案及供者选择的专家共识（2021 年版）
J Hematol Oncol. 2021 Sep 15;14(1):145. doi: 10.1186/s13045-021-01159-2.
9
Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.单倍体与同胞相合供者在成人急性淋巴细胞白血病造血干细胞移植中的结局：欧洲血液和骨髓移植学会急性白血病工作组的一项研究。
J Hematol Oncol. 2021 Apr 1;14(1):53. doi: 10.1186/s13045-021-01065-7.
10
Dynamic immune profiling identifies the stronger graft-versus-leukemia (GVL) effects with haploidentical allografts compared to HLA-matched stem cell transplantation.动态免疫分析显示，与 HLA 匹配的干细胞移植相比，半相合同种异体移植具有更强的移植物抗白血病（GVL）效应。
Cell Mol Immunol. 2021 May;18(5):1172-1185. doi: 10.1038/s41423-020-00597-1. Epub 2021 Jan 6.
Zotero 插件